1. Poland Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Ryvu Therapeutics S.A.

Ryvu Therapeutics S.A.

RVU.WA
Ryvu Therapeutics S.A.PL flagWarsaw Stock Exchange
14.96
PLN
-0.28
- -
345.88MMarket Cap
Ryvu Therapeutics S.A.
RVU.WA
(Warsaw Stock Exchange)

Recent

price

14.96

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.85
0.86
0.9
1.25
2.76
3.14
3.94
6.38
3.33
0.24
0.92
0.56
2.12
2.05
3.37
2.69
2.75
Revenue per Share
-0.19
-0.41
-0.61
-0.23
0.56
0.48
0.2
0.47
-1.49
17.88
-1.89
-4.31
-4.56
-4.02
-4.82
-4.38
-3.91
Basic EPS, GAAP
-0.69
-0.71
-85.08
-0.75
-0.48
-1.28
-0.66
0.06
-2.5
-2.59
-2.67
-3.86
0.66
-4.07
-5.86
-5.26
-4.42
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.04
-0.24
-0.85
-0.1
0.46
0.67
0.32
0.5
-0.59
18.76
15.65
9.98
5.42
0.4
-4.42
-8.8
-9.53
Book Value per Share
0.08
1.11
0.52
0.3
0.85
3.41
3.57
4.46
10.82
7.37
12.81
8.62
18.47
11.06
6.24
2.07
1.54
Tangible Book Value per Share
10
10
10
10
10
13
14
14
16
16
17
18
18
23
23
23
23
Basic Weighted Avg Shares
9
9
9
13
29
41
54
88
52
4
15
10
39
47
78
62
62
Sales/Revenue/Turnover
-33.51
-70.63
-66.5
-17.06
18.26
5.21
-2.09
14.43
-47.1
-1,194.87
-232.94
-775.85
-178.44
-207.8
-156.44
-156.15
-131.45
Operating Margin (%)
1
2
166
2
2
3
4
5
7
8
12
13
13
11
10
11
11
Depreciation Expense
-2
-4
-6
-2
6
6
3
6
-23
286
-32
-79
-84
-92
-111
-101
-89
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
29.88
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-22.31
-47.31
-68.24
-18.73
20.27
15.28
5.02
7.3
-44.61
7,520.15
-205.57
-763.45
-215.12
-196.57
-142.92
-162.61
-142.28
Profit Margin (%)
-4
7
1
- -
2
32
29
33
114
59
139
68
323
209
165
78
65
Working Capital
- -
- -
- -
- -
- -
- -
8
6
20
6
4
2
1
- -
66
71
73
LT Debt
2
12
6
3
9
47
56
64
170
121
217
161
343
260
152
54
41
Total Equity
- -
- -
- -
- -
- -
- -
- -
12.71
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
40.29
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
92.38
41.27
112.95
- -
- -
-11.28
-35.5
-59.28
-169.51
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
1
- -
- -
LT Borrowings
69
70
72
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
23
23
23
Market Capitalization
630
614
512

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
163
139
117
Cash, Cash Equivalents & STI
131
104
79
Accounts Receivable, Net
7
11
11
Inventories
1
1
1
Total Current Liabilities
72
62
52
Payables & Accruals
- -
- -
- -
ST Debt
1
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.75%
-8.64%
-64.65%
Free Cash Flow
-592.17%
-179.54%
-10.2%
Net Income, GAAP
-165.36%
35.45%
-9.16%
Sales/Revenue/Turnover
57.59%
61.95%
-20.15%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
22
16
15
26
78
2025
17
12
15
18
62
2026
17
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.84
-1.4
-1.1
- -
-4.82
2025
-1.09
-1.5
-1.1
- -
-4.38
2026
-0.55
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Reneo Pharmaceuticals, Inc. (RPHM)
Chengzhi Shareholding Co., Ltd. (000990.SZ)
Initiator Pharma A/S (INIT.ST)
Affimed N.V. (AFMD)
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
Lexaria Bioscience Corp. (LEXXW)
Business
Ryvu Therapeutics S.A. is a clinical-stage drug discovery and development company specializing in novel small molecule therapies targeting oncology. The company’s core products and services include selective kinase inhibitors and novel therapeutic candidates for hematological malignancies and solid tumors, with key programs such as RVU120, a CDK8/CDK19 kinase inhibitor in Phase II clinical trials for acute myeloid leukemia, myelodysplastic syndrome, and metastatic solid tumors; SEL24 (MEN1703), a dual PIM/FLT3 kinase inhibitor licensed to the Menarini Group, currently in Phase II clinical studies for acute myeloid leukemia; and RVU305, a brain-penetrant PRMT5 inhibitor targeting MTAP-deleted cancers. Ryvu also develops small molecules using diverse therapeutic mechanisms such as kinases, synthetic lethality, immunometabolism, and immuno-oncology, and advances antibody-drug conjugate (ADC) payload development. Geographically, Ryvu operates primarily in Poland and the wider European Union, with clinical trials extending into Canada and international collaborations. Founded in 2007 and headquartered in Kraków, Poland, Ryvu Therapeutics was formerly known as Selvita S.A., a name changed in 2019 to reflect a renewed focus on therapeutic development. Recent major changes include a strategic partnership with BioNTech to support clinical trial site activation and patient recruitment in Poland for multiple investigational cancer immunotherapies, leveraging Ryvu’s clinical network and operational expertise. Ryvu has also received a European Union grant for Phase II development of RVU305 targeting tumors with MTAP gene deletion, supporting its IND/CTA enabling studies expected to complete in late 2025. The company closed a significant equity offering netting over PLN 250 million ($57 million USD) in 2024 to fund ongoing development. Ryvu is expanding its oncology portfolio to include ADC projects planned for 2025-2026, aiming to innovate in antibody-linked drug technologies alongside its proprietary ONCO Prime discovery platform. These activities position Ryvu Therapeutics as a developer of precision oncology medicines with a strong pipeline of targeted small molecule therapies and strategic collaborations designed to accelerate development and clinical application across hematological and solid tumor indications in Europe and beyond.